{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:13:37Z","timestamp":1793171617887,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) has emerged as a novel strategy for modulating the tumour microenvironment (TME) by selectively eradicating FAP-expressing cancer-associated fibroblasts (CAFs). Although preclinical studies have demonstrated promising results across various tumour models using diverse radiolabelled FAP inhibitors, clinical translation remains limited by modest efficacy, short tumour retention, and highly heterogeneous responses. This review aims to provide an overview of recent advances in radiopharmaceutical design to enhance tumour targeting and prolong retention. Furthermore, we summarise early clinical findings and ongoing trials, while emphasising the potential translational challenges of FAP-TRT. Special emphasis is placed on the radiobiological underpinnings of FAP-TRT, including the impact of CAFs heterogeneity, potential pro-tumorigenic effects of sublethal irradiation, and the uncertain contribution of bystander and abscopal effects. We further highlight the need for the development of translationally relevant tumour models, optimised dosimetry, predictive biomarkers, and refined patient selection criteria. Finally, we propose future directions such as combination therapy with immune checkpoint inhibitors (ICIs). Together, these insights aim to bridge the gap between promising preclinical efficacy and limited clinical outcomes in FAP-TRT.<\/jats:p>","DOI":"10.1007\/s00259-025-07711-3","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T01:14:18Z","timestamp":1769994858000},"page":"4270-4296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective"],"prefix":"10.1007","volume":"53","author":[{"given":"Chunhui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Kurniawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihe","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines F.","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andor","family":"Glaudemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7581-3303","authenticated-orcid":false,"given":"Bart","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"7711_CR1","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/978-3-030-42618-7_29","volume":"216","author":"U Haberkorn","year":"2020","unstructured":"Haberkorn U, Kratochwil C, Giesel F. Internal radiation therapy. Recent Results Cancer Res. 2020;216:881\u2013902. https:\/\/doi.org\/10.1007\/978-3-030-42618-7_29.","journal-title":"Recent Results Cancer Res"},{"key":"7711_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.124.269215","volume":"66","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative. J Nucl Med. 2025;66:757\u201363. https:\/\/doi.org\/10.2967\/jnumed.124.269215.","journal-title":"J Nucl Med"},{"key":"7711_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/CCO.0000000000000762","volume":"33","author":"C Artigas","year":"2021","unstructured":"Artigas C, Mileva M, Flamen P, Karfis I. Targeted radionuclide therapy: an emerging field in solid tumours. Curr Opin Oncol. 2021;33:493\u20139. https:\/\/doi.org\/10.1097\/CCO.0000000000000762.","journal-title":"Curr Opin Oncol"},{"key":"7711_CR4","doi-asserted-by":"publisher","unstructured":"van der Wal BCH, Dadachova E. Targeted radionuclide therapy of cancer and infections. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24109081.","DOI":"10.3390\/ijms24109081"},{"key":"7711_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, Kurian M, Garcia JA, Mendiratta P, Barata PC, Jia AY, et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther. 2023;23:731\u201344. https:\/\/doi.org\/10.1080\/14737140.2023.2213892.","journal-title":"Expert Rev Anticancer Ther"},{"key":"7711_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1053\/j.semnuclmed.2024.02.002","volume":"54","author":"G Santo","year":"2024","unstructured":"Santo G, Di Santo G, Virgolini I. Peptide receptor radionuclide therapy of neuroendocrine tumors: Agonist, antagonist and alternatives. Semin Nucl Med. 2024;54:557\u201369. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.002.","journal-title":"Semin Nucl Med"},{"key":"7711_CR7","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3892\/mmr.2015.3197","volume":"11","author":"F Zi","year":"2015","unstructured":"Zi F, He J, He D, Li Y, Yang L, Cai Z. Fibroblast activation protein \u03b1 in tumor microenvironment: recent progression and implications (review). Mol Med Rep. 2015;11:3203\u201311. https:\/\/doi.org\/10.3892\/mmr.2015.3197.","journal-title":"Mol Med Rep"},{"key":"7711_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783\u2013803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3.","journal-title":"Cancer Metastasis Rev"},{"key":"7711_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398. https:\/\/doi.org\/10.1038\/nrc.2016.73.","journal-title":"Nat Rev Cancer"},{"key":"7711_CR10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/mc.23782","volume":"63","author":"X Zhou","year":"2024","unstructured":"Zhou X, Tong Y, Yu C, Pu J, Zhu W, Zhou Y, et al. FAP positive cancer-associated fibroblasts promote tumor progression and radioresistance in esophageal squamous cell carcinoma by transferring Exosomal LncRNA AFAP1-AS1. Mol Carcinog. 2024;63:1922\u201337. https:\/\/doi.org\/10.1002\/mc.23782.","journal-title":"Mol Carcinog"},{"key":"7711_CR11","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.08.003","author":"AA \u00d6zt\u00fcrk","year":"2025","unstructured":"\u00d6zt\u00fcrk AA, Delbart W, Flamen P. Expanding the horizon of targeted radionuclide therapy: immunotherapy combinations and FAP-Targeted approaches. Semin Nucl Med. 2025. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.08.003.","journal-title":"Semin Nucl Med"},{"key":"7711_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","volume":"64","author":"M Ora","year":"2023","unstructured":"Ora M, Soni N, Nazar AH, Dixit M, Singh R, Puri S, et al. Fibroblast activation protein Inhibitor-Based radionuclide therapies: current status and future directions. J Nucl Med. 2023;64:1001\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265594.","journal-title":"J Nucl Med"},{"key":"7711_CR13","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","volume":"64","author":"M Ora","year":"2023","unstructured":"Ora M, Soni N, Nazar AH, Dixit M, Singh R, Puri S, et al. Fibroblast activation protein Inhibitor-Based radionuclide therapies: current status and future directions. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2023;64:1001\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.265594.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7711_CR14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268689","author":"R Wang","year":"2025","unstructured":"Wang R, Huang M, Wang W, Li M, Wang Y, Tian R. Preclinical evaluation of (68)Ga\/(177)Lu-Labeled FAP-Targeted peptide for tumor radiopharmaceutical imaging and therapy. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.268689.","journal-title":"J Nucl Med"},{"key":"7711_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00259-024-06914-4","volume":"52","author":"H Ceuppens","year":"2025","unstructured":"Ceuppens H, Pombo Antunes AR, Navarro L, Ertveldt T, Berdal M, Nagachinta S, et al. Efficient \u03b1 and \u03b2(-) radionuclide therapy targeting fibroblast activation protein-\u03b1 in an aggressive preclinical mouse tumour model. Eur J Nucl Med Mol Imaging. 2025;52:444\u201357. https:\/\/doi.org\/10.1007\/s00259-024-06914-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3918","author":"H Fu","year":"2025","unstructured":"Fu H, Huang J, Zhao L, Chen Y, Xu W, Cai J, et al. 177Lu-LNC1004 radioligand therapy in patients with End-stage metastatic cancers: A Single-Center, Single-Arm, phase II study. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3918.","journal-title":"Clin Cancer Res"},{"key":"7711_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/rlu.0000000000005297","volume":"49","author":"Y Xie","year":"2024","unstructured":"Xie Y, Ma J, Tang W, Zhang Y, Zhang C, Chen Y. Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer. Clin Nucl Med. 2024;49:830\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000005297.","journal-title":"Clin Nucl Med"},{"key":"7711_CR18","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2967\/jnumed.124.268386","volume":"65","author":"A Helisch","year":"2024","unstructured":"Helisch A, Kratochwil C, Kleist C, Kr\u00e4mer S, Rosales Castillo JJ, Dendl K, et al. Feasibility, Tolerability, and preliminary clinical response of fractionated radiopharmaceutical therapy with (213)Bi-FAPI-46: pilot experience in patients with End-Stage, progressive metastatic tumors. J Nucl Med. 2024;65:1917\u201322. https:\/\/doi.org\/10.2967\/jnumed.124.268386.","journal-title":"J Nucl Med"},{"key":"7711_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnumed.123.266411","volume":"65","author":"R Hamacher","year":"2024","unstructured":"Hamacher R, Pabst KM, Cheung PF, Heilig CE, H\u00fcllein J, Liffers ST, et al. Fibroblast activation protein \u03b1-Directed imaging and therapy of solitary fibrous tumor. J Nucl Med. 2024;65:252\u20137. https:\/\/doi.org\/10.2967\/jnumed.123.266411.","journal-title":"J Nucl Med"},{"key":"7711_CR20","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/rlu.0000000000005255","volume":"49","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Bayat M, Pirayesh E, Divband G, Abolhosseini A, Akbari ME. First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med. 2024;49:e334\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000005255.","journal-title":"Clin Nucl Med"},{"key":"7711_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237\u201346. https:\/\/doi.org\/10.1007\/s00259-024-06795-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR22","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.Ccr-23-1983","volume":"29","author":"H Fu","year":"2023","unstructured":"Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, et al. Fibroblast activation Protein-Targeted radioligand therapy with 177Lu-EB-FAPI for metastatic Radioiodine-Refractory thyroid cancer: First-in-Human, Dose-Escalation study. Clin Cancer Res. 2023;29:4740\u201350. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1983.","journal-title":"Clin Cancer Res"},{"key":"7711_CR23","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","volume":"47","author":"F Kaghazchi","year":"2022","unstructured":"Kaghazchi F, Aghdam RA, Haghighi S, Vali R, Adinehpour Z. 177Lu-FAPI therapy in a patient with End-Stage metastatic pancreatic adenocarcinoma. Clin Nucl Med. 2022;47:e243\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000004021.","journal-title":"Clin Nucl Med"},{"key":"7711_CR24","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00259-021-05634-3","volume":"49","author":"K Fu","year":"2022","unstructured":"Fu K, Pang Y, Zhao L, Lin L, Wu H, Sun L, et al. FAP-targeted radionuclide therapy with [(177)Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49:1767\u20139. https:\/\/doi.org\/10.1007\/s00259-021-05634-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/rlu.0000000000004260","volume":"47","author":"H Fu","year":"2022","unstructured":"Fu H, Huang J, Sun L, Wu H, Chen H. FAP-Targeted radionuclide therapy of advanced Radioiodine-Refractory differentiated thyroid cancer with multiple cycles of 177 Lu-FAPI-46. Clin Nucl Med. 2022;47:906\u20137. https:\/\/doi.org\/10.1097\/rlu.0000000000004260.","journal-title":"Clin Nucl Med"},{"key":"7711_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2967\/jnumed.121.262468","volume":"63","author":"J Ferdinandus","year":"2022","unstructured":"Ferdinandus J, Costa PF, Kessler L, Weber M, Hirmas N, Kostbade K, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for Advanced-Stage solid tumors: A case series of 9 patients. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2022;63:727\u201334. https:\/\/doi.org\/10.2967\/jnumed.121.262468.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7711_CR27","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","volume":"28","author":"WP Fendler","year":"2022","unstructured":"Fendler WP, Pabst KM, Kessler L, Fragoso Costa P, Ferdinandus J, Weber M, et al. Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities. Clin Cancer Res. 2022;28:4346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1432.","journal-title":"Clin Cancer Res"},{"key":"7711_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, Biodistribution, and preliminary dosimetry in Peptide-Targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: First-in-Humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"key":"7711_CR29","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1097\/RLU.0000000000004051","volume":"47","author":"S Barashki","year":"2022","unstructured":"Barashki S, Divband G, Askari E, Amini H, Aryana K. Fibroblast activation protein inhibitor imaging and therapy in a patient with multiple endocrine neoplasia type 2A syndrome. Clin Nucl Med. 2022;47:e284\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000004051.","journal-title":"Clin Nucl Med"},{"key":"7711_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/thy.2021.0412","volume":"32","author":"S Ballal","year":"2022","unstructured":"Ballal S, Yadav MP, Moon ES, Roesch F, Kumari S, Agarwal S, et al. Novel fibroblast activation protein Inhibitor-Based targeted theranostics for Radioiodine-Refractory differentiated thyroid cancer patients: A pilot study. Thyroid: Official J Am Thyroid Association. 2022;32:65\u201377. https:\/\/doi.org\/10.1089\/thy.2021.0412.","journal-title":"Thyroid: Official J Am Thyroid Association"},{"key":"7711_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/RLU.0000000000003842","volume":"46","author":"H Rathke","year":"2021","unstructured":"Rathke H, Fuxius S, Giesel FL, Lindner T, Debus J, Haberkorn U, et al. Two Tumors, one target: preliminary experience with 90Y-FAPI therapy in a patient with metastasized breast and colorectal cancer. Clin Nucl Med. 2021;46:842\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000003842.","journal-title":"Clin Nucl Med"},{"key":"7711_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/rlu.0000000000003667","volume":"46","author":"S Kuyumcu","year":"2021","unstructured":"Kuyumcu S, Kovan B, Sanli Y, Buyukkaya F, Has Simsek D, \u00d6zkan ZG, et al. Safety of fibroblast activation Protein-Targeted radionuclide therapy by a Low-Dose dosimetric approach using 177Lu-FAPI04. Clin Nucl Med. 2021;46:641\u20136. https:\/\/doi.org\/10.1097\/rlu.0000000000003667.","journal-title":"Clin Nucl Med"},{"key":"7711_CR33","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","volume":"48","author":"C Kratochwil","year":"2021","unstructured":"Kratochwil C, Giesel FL, Rathke H, Fink R, Dendl K, Debus J, et al. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021;48:3011\u20133. https:\/\/doi.org\/10.1007\/s00259-021-05273-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR34","doi-asserted-by":"publisher","unstructured":"BallalS,Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S et al. First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2. Pharmaceuticals (Basel). 2021;14. https:\/\/doi.org\/10.3390\/ph14121212.","DOI":"10.3390\/ph14121212"},{"key":"7711_CR35","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","volume":"48","author":"S Ballal","year":"2021","unstructured":"Ballal S, Yadav MP, Kramer V, Moon ES, Roesch F, Tripathi M, et al. A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:942\u20134. https:\/\/doi.org\/10.1007\/s00259-020-04990-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR36","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/rlu.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177Lu-Fibroblast activation protein Inhibitor-46 for patients with relapsed or refractory cancers: A preliminary study. Clin Nucl Med. 2021;46:e523\u201330. https:\/\/doi.org\/10.1097\/rlu.0000000000003810.","journal-title":"Clin Nucl Med"},{"key":"7711_CR37","doi-asserted-by":"publisher","unstructured":"Becx MN, Minczeles NS, Brabander T, de Herder WW, Nonnekens J, Hofland J. A clinical guide to peptide receptor radionuclide therapy with (177)Lu-DOTATATE in neuroendocrine tumor patients. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14235792.","DOI":"10.3390\/cancers14235792"},{"key":"7711_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11523-024-01117-1","volume":"20","author":"C Ciccarese","year":"2025","unstructured":"Ciccarese C, Bauckneht M, Zagaria L, Fornarini G, Beccia V, Lanfranchi F, et al. Defining the position of [(177)Lu]Lu-PSMA radioligand therapy in the treatment landscape of metastatic Castration-Resistant prostate cancer: A Meta-analysis of clinical trials. Target Oncol. 2025;20:103\u201312. https:\/\/doi.org\/10.1007\/s11523-024-01117-1.","journal-title":"Target Oncol"},{"key":"7711_CR39","doi-asserted-by":"publisher","first-page":"s4","DOI":"10.2967\/jnumed.123.266983","volume":"65","author":"L Zhao","year":"2024","unstructured":"Zhao L, Kang F, Pang Y, Fang J, Sun L, Wu H, et al. Fibroblast activation protein inhibitor tracers and their Preclinical, Translational, and clinical status in China. J Nucl Med. 2024;65:s4\u201311. https:\/\/doi.org\/10.2967\/jnumed.123.266983.","journal-title":"J Nucl Med"},{"key":"7711_CR40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","volume":"49","author":"Y Liu","year":"2022","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, et al. Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2022;49:871\u201380. https:\/\/doi.org\/10.1007\/s00259-021-05554-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR41","doi-asserted-by":"publisher","first-page":"116238","DOI":"10.1016\/j.ejmech.2024.116238","volume":"268","author":"S Bendre","year":"2024","unstructured":"Bendre S, Merkens H, Kuo HT, Ng P, Wong A, Lau WS, et al. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-\u03b1-targeted radiotheranostic for cancer imaging and therapy. Eur J Med Chem. 2024;268:116238. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116238.","journal-title":"Eur J Med Chem"},{"key":"7711_CR42","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","volume":"63","author":"M Xu","year":"2022","unstructured":"Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Albumin Binder-Conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy. J Nucl Med. 2022;63:952\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262533.","journal-title":"J Nucl Med"},{"key":"7711_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/thno.68182","volume":"12","author":"X Wen","year":"2022","unstructured":"Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12:422\u201333. https:\/\/doi.org\/10.7150\/thno.68182.","journal-title":"Theranostics"},{"key":"7711_CR44","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.1021\/acs.jmedchem.1c02162","volume":"65","author":"L Meng","year":"2022","unstructured":"Meng L, Fang J, Zhao L, Wang T, Yuan P, Zhao Z, et al. Rational design and pharmacomodulation of protein-Binding theranostic radioligands for targeting the fibroblast activation protein. J Med Chem. 2022;65:8245\u201357. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02162.","journal-title":"J Med Chem"},{"key":"7711_CR45","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","volume":"49","author":"P Zhang","year":"2022","unstructured":"Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, et al. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2022;49:1985\u201396. https:\/\/doi.org\/10.1007\/s00259-021-05591-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR46","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","volume":"50","author":"J Millul","year":"2023","unstructured":"Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023;50:3050\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06272-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR47","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2967\/jnumed.124.267756","volume":"65","author":"R Mukkamala","year":"2024","unstructured":"Mukkamala R, Carlson DJ, Miller NK, Lindeman SD, Bowen ER, Tudi P, et al. Design of a fibroblast activation Protein-Targeted radiopharmaceutical therapy with high Tumor-to-Healthy-Tissue ratios. J Nucl Med. 2024;65:1257\u201363. https:\/\/doi.org\/10.2967\/jnumed.124.267756.","journal-title":"J Nucl Med"},{"key":"7711_CR48","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1021\/acs.jmedchem.4c00448","volume":"67","author":"SD Lindeman","year":"2024","unstructured":"Lindeman SD, Booth OC, Tudi P, Schleinkofer TC, Moss JN, Kearney NB, et al. FAP radioligand linker optimization improves tumor dose and tumor-to-Healthy organ ratios in 4T1 syngeneic model. J Med Chem. 2024;67:11827\u201340. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00448.","journal-title":"J Med Chem"},{"key":"7711_CR49","doi-asserted-by":"publisher","unstructured":"Aso A, Nabetani H, Matsuura Y, Kadonaga Y, Shirakami Y, Watabe T, et al. Evaluation of Astatine-211-Labeled fibroblast activation protein inhibitor (FAPI): comparison of different linkers with polyethylene glycol and piperazine. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24108701.","DOI":"10.3390\/ijms24108701"},{"key":"7711_CR50","doi-asserted-by":"publisher","first-page":"17785","DOI":"10.1021\/acs.jmedchem.4c01812","volume":"67","author":"J Huang","year":"2024","unstructured":"Huang J, Zhang X, Liu Q, Gong F, Huang Y, Huang S, et al. (68)Ga\/(177)Lu-Labeled theranostic pair for targeting fibroblast activation protein with improved tumor uptake and retention. J Med Chem. 2024;67:17785\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01812.","journal-title":"J Med Chem"},{"key":"7711_CR51","doi-asserted-by":"publisher","unstructured":"Abe K, Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Naka S, et al Evaluation of targeted alpha therapy using [(211)At]FAPI1 in triple-negative breast cancer xenograft models. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms252111567.","DOI":"10.3390\/ijms252111567"},{"key":"7711_CR52","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1007\/s00259-023-06230-3","volume":"50","author":"Y Liu","year":"2023","unstructured":"Liu Y, Tang H, Song T, Xu M, Chen J, Cui XY, et al. Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2023;50:2636\u201346. https:\/\/doi.org\/10.1007\/s00259-023-06230-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR53","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00259-023-06169-5","volume":"50","author":"T Yang","year":"2023","unstructured":"Yang T, Peng L, Qiu J, He X, Zhang D, Wu R, et al. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2023;50:2331\u201341. https:\/\/doi.org\/10.1007\/s00259-023-06169-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR54","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","volume":"19","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y, Fang J, Fu K, Meng L, et al. Development of fibroblast activation protein Inhibitor-Based dimeric radiotracers with improved tumor retention and antitumor efficacy. Mol Pharm. 2022;19:3640\u201351. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00424.","journal-title":"Mol Pharm"},{"key":"7711_CR55","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang Y, Zhao L, Fang J, Chen J, Meng L, Sun L, et al. Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy. J Nucl Med. 2023;64:1449\u201355. https:\/\/doi.org\/10.2967\/jnumed.123.265599.","journal-title":"J Nucl Med"},{"key":"7711_CR56","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651\u201367. https:\/\/doi.org\/10.1007\/s00259-022-05842-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2967\/jnumed.123.266345","volume":"65","author":"SE Poplawski","year":"2024","unstructured":"Poplawski SE, Hallett RM, Dornan MH, Novakowski KE, Pan S, Belanger AP, et al. Preclinical development of PNT6555, a boronic Acid-Based, fibroblast activation Protein-\u03b1 (FAP)-Targeted radiotheranostic for imaging and treatment of FAP-Positive tumors. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2024;65:100\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266345.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7711_CR58","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1007\/s00259-022-05933-3","volume":"49","author":"S Boinapally","year":"2022","unstructured":"Boinapally S, Lisok A, Lofland G, Minn I, Yan Y, Jiang Z, et al. Hetero-bivalent agents targeting FAP and PSMA. Eur J Nucl Med Mol Imaging. 2022;49:4369\u201381. https:\/\/doi.org\/10.1007\/s00259-022-05933-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR59","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00259-024-06623-y","volume":"51","author":"K Liu","year":"2024","unstructured":"Liu K, Jiang T, Rao W, Chen B, Yin X, Xu P, et al. Peptidic heterodimer-based Radiotracer targeting fibroblast activation protein and integrin \u03b1v\u03b23. Eur J Nucl Med Mol Imaging. 2024;51:1544\u201357. https:\/\/doi.org\/10.1007\/s00259-024-06623-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR60","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","volume":"630","author":"X-Y Cui","year":"2024","unstructured":"Cui X-Y, Li Z, Kong Z, Liu Y, Meng H, Wen Z, et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024;630:206\u201313. https:\/\/doi.org\/10.1038\/s41586-024-07461-6.","journal-title":"Nature"},{"key":"7711_CR61","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A phase I dose-escalation study of Sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639\u201347.","journal-title":"Clin Cancer Res"},{"key":"7711_CR62","first-page":"729","volume":"2","author":"K Tahtis","year":"2003","unstructured":"Tahtis K, Lee F-T, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, et al. Expression and targeting of human fibroblast activation protein in a human skin\/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther. 2003;2:729\u201337.","journal-title":"Mol Cancer Ther"},{"key":"7711_CR63","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1158\/1078-0432.CCR-12-0644","volume":"18","author":"E Fischer","year":"2012","unstructured":"Fischer E, Chaitanya K, W\u00fcest T, Wadle A, Scott AM, van den Broek M, et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res. 2012;18:6208\u201318. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0644.","journal-title":"Clin Cancer Res"},{"key":"7711_CR64","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1007\/s00259-023-06300-6","volume":"50","author":"M Xu","year":"2023","unstructured":"Xu M, Chen J, Zhang P, Cai J, Song H, Li Z, et al. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy. Eur J Nucl Med Mol Imaging. 2023;50:3214\u201324. https:\/\/doi.org\/10.1007\/s00259-023-06300-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR65","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/cbmi.3c00067","volume":"1","author":"H Song","year":"2023","unstructured":"Song H, Xu M, Cai J, Chen J, Liu Y, Su Q, et al. (225)Ac-Labeled antibody for fibroblast activation Protein-Targeted alpha therapy. Chem Biomed Imaging. 2023;1:628\u201336. https:\/\/doi.org\/10.1021\/cbmi.3c00067.","journal-title":"Chem Biomed Imaging"},{"key":"7711_CR66","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.123.266381","volume":"64","author":"Y Dekempeneer","year":"2023","unstructured":"Dekempeneer Y, Massa S, Santens F, Navarro L, Berdal M, Lucero MM, et al. Preclinical evaluation of a radiotheranostic Single-Domain antibody against fibroblast activation protein \u03b1. J Nucl Med. 2023;64:1941\u20138. https:\/\/doi.org\/10.2967\/jnumed.123.266381.","journal-title":"J Nucl Med"},{"key":"7711_CR67","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2967\/jnumed.124.267624","volume":"65","author":"S Poty","year":"2024","unstructured":"Poty S, Ordas L, Dekempeneer Y, Parach AA, Navarro L, Santens F, et al. Optimizing the therapeutic index of sdAb-Based radiopharmaceuticals using pretargeting. J Nucl Med. 2024;65:1564\u201370. https:\/\/doi.org\/10.2967\/jnumed.124.267624.","journal-title":"J Nucl Med"},{"key":"7711_CR68","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1007\/s00259-024-06809-4","volume":"51","author":"MF Taddio","year":"2024","unstructured":"Taddio MF, Doshi S, Masri M, Jeanjean P, Hikmat F, Gerlach A, et al. Evaluating [(225)Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice. Eur J Nucl Med Mol Imaging. 2024;51:4026\u201337. https:\/\/doi.org\/10.1007\/s00259-024-06809-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR69","doi-asserted-by":"publisher","unstructured":"Chen J, Zhou Y, Pang Y, Fu K, Luo Q, Sun L, et al. FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer. 2025;13. https:\/\/doi.org\/10.1136\/jitc-2024-010212.","DOI":"10.1136\/jitc-2024-010212"},{"key":"7711_CR70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pang Y, Zhou Y, Chen J, Fu H, Guo W, et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint Blockade. Signal Transduct Target Ther. 2024;9:142. https:\/\/doi.org\/10.1038\/s41392-024-01853-w.","journal-title":"Signal Transduct Target Ther"},{"key":"7711_CR71","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.1038\/s41598-025-91716-3","volume":"15","author":"A Shirpour","year":"2025","unstructured":"Shirpour A, Hadadi A, Zolghadri S, Vosoughi S, Rajabifar S. Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein. Sci Rep-Uk. 2025;15:7475. https:\/\/doi.org\/10.1038\/s41598-025-91716-3.","journal-title":"Sci Rep-Uk"},{"key":"7711_CR72","doi-asserted-by":"publisher","first-page":"116919","DOI":"10.1016\/j.ejmech.2024.116919","volume":"279","author":"T Ye","year":"2024","unstructured":"Ye T, Yu Y, Qu G, Ma H, Shi S, Ji J, et al. (211)At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma. Eur J Med Chem. 2024;279:116919. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116919.","journal-title":"Eur J Med Chem"},{"key":"7711_CR73","doi-asserted-by":"publisher","unstructured":"Wang Y, Qiu L, Ye T, Tan F, Lyu J, Li F, et al. (177)Lu radiolabeled polydopamine decorated with fibroblast activation protein inhibitor for locoregional treatment of glioma. ChemBioChem. 2024;e202400579. https:\/\/doi.org\/10.1002\/cbic.202400579.","DOI":"10.1002\/cbic.202400579"},{"key":"7711_CR74","doi-asserted-by":"publisher","unstructured":"Hisada K, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Saito A, Watabe T, et al. Comparison length of linker in compound for nuclear medicine targeting fibroblast activation protein as molecular target. Int J Mol Sci. 2024;25. https:\/\/doi.org\/10.3390\/ijms252212296.","DOI":"10.3390\/ijms252212296"},{"key":"7711_CR75","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1021\/acs.molpharmaceut.2c00965","volume":"20","author":"X Zhong","year":"2023","unstructured":"Zhong X, Guo J, Han X, Wu W, Yang R, Zhang J, et al. Synthesis and preclinical evaluation of a novel FAPI-04 dimer for cancer theranostics. Mol Pharm. 2023;20:2402\u201314. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00965.","journal-title":"Mol Pharm"},{"key":"7711_CR76","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acs.molpharmaceut.1c00566","volume":"18","author":"H Ma","year":"2021","unstructured":"Ma H, Li F, Shen G, Cai H, Liu W, Lan T, et al. Synthesis and preliminary evaluation of (131)I-Labeled FAPI tracers for cancer theranostics. Mol Pharm. 2021;18:4179\u201387. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00566.","journal-title":"Mol Pharm"},{"key":"7711_CR77","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.233122.","journal-title":"J Nucl Med"},{"key":"7711_CR78","doi-asserted-by":"publisher","first-page":"2480493","DOI":"10.1155\/2023\/2480493","volume":"2023","author":"JN Crane","year":"2023","unstructured":"Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, et al. Fibroblast activation protein expression in sarcomas. Sarcoma. 2023;2023:2480493. https:\/\/doi.org\/10.1155\/2023\/2480493.","journal-title":"Sarcoma"},{"key":"7711_CR79","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-12-0372","volume":"18","author":"S Julien","year":"2012","unstructured":"Julien S, Merino-Trigo A, Lacroix L, Pocard M, Go\u00e9r\u00e9 D, Mariani P, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18:5314\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0372.","journal-title":"Clin Cancer Res"},{"key":"7711_CR80","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bcp.2014.06.008","volume":"91","author":"E Rosfjord","year":"2014","unstructured":"Rosfjord E, Lucas J, Li G, Gerber H-P. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol. 2014;91:135\u201343. https:\/\/doi.org\/10.1016\/j.bcp.2014.06.008.","journal-title":"Biochem Pharmacol"},{"key":"7711_CR81","doi-asserted-by":"publisher","first-page":"109571","DOI":"10.1016\/j.nucmedbio.2025.109571","volume":"150\u2013151","author":"CD van der Heide","year":"2025","unstructured":"van der Heide CD, McMorrow R, Gama-Franceschi F, Doukas M, Mezzanotte L, Dalm SU. Illuminating radionuclide therapy response: monitoring cancer cell and CAF survival in a direct 2D co-culture model. Nucl Med Biol. 2025;150\u2013151:109571. https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109571.","journal-title":"Nucl Med Biol"},{"key":"7711_CR82","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13550-024-01191-6","volume":"14","author":"CD van der Heide","year":"2024","unstructured":"van der Heide CD, Campeiro JD, Ruigrok EAM, van den Brink L, Ponnala S, Hillier SM, et al. In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for Radiotracer evaluation. EJNMMI Res. 2024;14:125. https:\/\/doi.org\/10.1186\/s13550-024-01191-6.","journal-title":"EJNMMI Res"},{"key":"7711_CR83","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semcancer.2022.04.008","volume":"86","author":"A Peltier","year":"2022","unstructured":"Peltier A, Seban RD, Buvat I, Bidard FC, Mechta-Grigoriou F. Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging. Semin Cancer Biol. 2022;86:262\u201372. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.008.","journal-title":"Semin Cancer Biol"},{"key":"7711_CR84","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.Cd-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-Cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10:1330\u201351. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-1384.","journal-title":"Cancer Discov"},{"key":"7711_CR85","doi-asserted-by":"publisher","unstructured":"Maia A, Wiemann S. Cancer-Associated fibroblasts: implications for cancer therapy. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13143526.","DOI":"10.3390\/cancers13143526"},{"key":"7711_CR86","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.3892\/ol.2018.9836","volume":"17","author":"B Koh","year":"2019","unstructured":"Koh B, Jeon H, Kim D, Kang D, Kim KR. Effect of fibroblast co-culture on the proliferation, viability and drug response of colon cancer cells. Oncol Lett. 2019;17:2409\u201317. https:\/\/doi.org\/10.3892\/ol.2018.9836.","journal-title":"Oncol Lett"},{"key":"7711_CR87","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-Induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282\u2013301. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0710.","journal-title":"Cancer Discov"},{"key":"7711_CR88","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719\u201334. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.005.","journal-title":"Cancer Cell"},{"key":"7711_CR89","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","volume":"9","author":"M Bartoschek","year":"2018","unstructured":"Bartoschek M, Oskolkov N, Bocci M, L\u00f6vrot J, Larsson C, Sommarin M, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9:5150. https:\/\/doi.org\/10.1038\/s41467-018-07582-3.","journal-title":"Nat Commun"},{"key":"7711_CR90","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214:579\u201396. https:\/\/doi.org\/10.1084\/jem.20162024.","journal-title":"J Exp Med"},{"key":"7711_CR91","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ccell.2021.05.010","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39:883. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.010.","journal-title":"Cancer Cell"},{"key":"7711_CR92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12964-023-01093-5","volume":"21","author":"I Martinez-Zubiaurre","year":"2023","unstructured":"Martinez-Zubiaurre I, Hellevik T. Cancer-associated fibroblasts in radiotherapy: bystanders or protagonists? Cell Commun Signal. 2023;21:108. https:\/\/doi.org\/10.1186\/s12964-023-01093-5.","journal-title":"Cell Commun Signal"},{"key":"7711_CR93","first-page":"2192","volume":"6","author":"D Li","year":"2016","unstructured":"Li D, Qu C, Ning Z, Wang H, Zang K, Zhuang L, et al. Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. Am J Cancer Res. 2016;6:2192\u2013206.","journal-title":"Am J Cancer Res"},{"key":"7711_CR94","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12964-025-02138-7","volume":"23","author":"L Zheng","year":"2025","unstructured":"Zheng L, Cai W, Ke Y, Hu X, Yang C, Zhang R, et al. Cancer\u2013associated fibroblasts: a pivotal regulator of tumor microenvironment in the context of radiotherapy. Cell Commun Signal. 2025;23:147. https:\/\/doi.org\/10.1186\/s12964-025-02138-7.","journal-title":"Cell Commun Signal"},{"key":"7711_CR95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","volume":"31","author":"ZS Morris","year":"2021","unstructured":"Morris ZS, Wang AZ, Knox SJ. The radiobiology of radiopharmaceuticals. Semin Radiat Oncol. 2021;31:20\u20137. https:\/\/doi.org\/10.1016\/j.semradonc.2020.07.002.","journal-title":"Semin Radiat Oncol"},{"key":"7711_CR96","doi-asserted-by":"publisher","first-page":"6075403","DOI":"10.1155\/2018\/6075403","volume":"2018","author":"A Avagliano","year":"2018","unstructured":"Avagliano A, Granato G, Ruocco MR, Romano V, Belviso I, Carfora A, et al. Metabolic reprogramming of cancer associated fibroblasts: the slavery of stromal fibroblasts. Biomed Res Int. 2018;2018:6075403. https:\/\/doi.org\/10.1155\/2018\/6075403.","journal-title":"Biomed Res Int"},{"key":"7711_CR97","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392\u2013401.","journal-title":"Nat Rev Cancer"},{"key":"7711_CR98","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fmed.2015.00012","volume":"2","author":"J-P Pouget","year":"2015","unstructured":"Pouget J-P, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12. https:\/\/doi.org\/10.3389\/fmed.2015.00012.","journal-title":"Front Med"},{"key":"7711_CR99","doi-asserted-by":"publisher","unstructured":"Fouillet J, Torchio J, Rubira L, Fersing C Unveiling the tumor microenvironment through fibroblast activation protein targeting in diagnostic nuclear medicine: a didactic review on biological rationales and key imaging agents. Biology (Basel). 2024;13. https:\/\/doi.org\/10.3390\/biology13120967.","DOI":"10.3390\/biology13120967"},{"key":"7711_CR100","doi-asserted-by":"publisher","first-page":"e7965","DOI":"10.1371\/journal.pone.0007965","volume":"4","author":"D Liao","year":"2009","unstructured":"Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE. 2009;4:e7965. https:\/\/doi.org\/10.1371\/journal.pone.0007965.","journal-title":"PLoS ONE"},{"key":"7711_CR101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12307-010-0044-5","volume":"3","author":"JL Barnas","year":"2010","unstructured":"Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron. 2010;3:29\u201347. https:\/\/doi.org\/10.1007\/s12307-010-0044-5.","journal-title":"Cancer Microenviron"},{"key":"7711_CR102","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/onc.2017.65","volume":"36","author":"N Cohen","year":"2017","unstructured":"Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of chitinase 3-like 1. Oncogene. 2017;36:4457\u201368. https:\/\/doi.org\/10.1038\/onc.2017.65.","journal-title":"Oncogene"},{"key":"7711_CR103","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1007\/s00259-005-1877-x","volume":"32","author":"A Capello","year":"2005","unstructured":"Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2005;32:1288\u201395. https:\/\/doi.org\/10.1007\/s00259-005-1877-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7711_CR104","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l","volume":"92","author":"M de Jong","year":"2001","unstructured":"de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628\u201333. https:\/\/doi.org\/10.1002\/1097-0215(20010601)92:5%3C628::aid-ijc1244%3E3.0.co;2-l.","journal-title":"Int J Cancer"},{"key":"7711_CR105","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40658-022-00497-5","volume":"9","author":"J Tranel","year":"2022","unstructured":"Tranel J, Palm S, Graves SA, Feng FY, Hope TA. Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model. EJNMMI Phys. 2022;9:67. https:\/\/doi.org\/10.1186\/s40658-022-00497-5.","journal-title":"EJNMMI Phys"},{"key":"7711_CR106","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","volume":"61","author":"TG Chan","year":"2020","unstructured":"Chan TG, O\u2019Neill E, Habjan C, Cornelissen B. Combination strategies to improve targeted radionuclide therapy. J Nucl Med. 2020;61:1544\u201352. https:\/\/doi.org\/10.2967\/jnumed.120.248062.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07711-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:30:00Z","timestamp":1781631000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07711-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7711"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07711-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not report on or involve any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}